Core Viewpoint - Stevanato Group reported quarterly earnings of $0.13 per share, matching the Zacks Consensus Estimate, but down from $0.16 per share a year ago [1] - The company generated revenues of $305.42 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 1.89% and up from $295.39 million year-over-year [2] Financial Performance - Over the last four quarters, Stevanato has not surpassed consensus EPS estimates [2] - The company has topped consensus revenue estimates two times in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.19 on revenues of $355.64 million, and for the current fiscal year, it is $0.50 on revenues of $1.2 billion [7] Stock Performance - Stevanato shares have declined approximately 29% since the beginning of the year, contrasting with the S&P 500's gain of 19.8% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [6] Industry Outlook - The Medical - Drugs industry, to which Stevanato belongs, is currently in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - Stevanato Group reported quarterly earnings of $0.10 per share, matching the Zacks Consensus Estimate, but down from $0.15 per share a year ago [1] - The company generated revenues of $279.44 million for the quarter ended June 2024, exceeding the Zacks Consensus Estimate by 1.43% and slightly up from $277.92 million year-over-year [2] - Stevanato shares have declined approximately 31.2% year-to-date, contrasting with the S&P 500's gain of 8.7% [3] Earnings Performance - Over the last four quarters, Stevanato has not surpassed consensus EPS estimates, with only one instance of exceeding revenue estimates [2] - The current consensus EPS estimate for the upcoming quarter is $0.15, with projected revenues of $312.49 million, and for the current fiscal year, the estimate is $0.53 on revenues of $1.22 billion [7] Market Outlook - The estimate revisions trend for Stevanato is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The Medical - Drugs industry, to which Stevanato belongs, is ranked in the top 42% of over 250 Zacks industries, suggesting a potential for better performance compared to lower-ranked industries [8]

Core Viewpoint - Stevanato Group (STVN) is anticipated to report a year-over-year decline in earnings and revenues for the quarter ended June 2024, which could significantly impact its stock price depending on the actual results compared to expectations [2][12]. Financial Performance Expectations - The expected quarterly earnings for Stevanato are $0.10 per share, reflecting a year-over-year decrease of 33.3% [3]. - Revenues are projected to be $274.59 million, down 1.2% from the same quarter last year [4]. Analyst Sentiment and Estimates - The Most Accurate Estimate for Stevanato is lower than the Zacks Consensus Estimate, indicating a bearish outlook from analysts, resulting in an Earnings ESP of -2.44% [8]. - Over the last 30 days, the consensus EPS estimate has been revised 2.22% lower, showing a collective reassessment by covering analysts [16]. Earnings Surprise History - Stevanato has beaten consensus EPS estimates only once in the last four quarters [10]. - In the last reported quarter, the company was expected to post earnings of $0.12 per share but actually reported $0.09, resulting in a surprise of -25% [22]. Zacks Rank and Predictive Power - Stevanato currently holds a Zacks Rank of 4 (Sell), which complicates the prediction of an earnings beat [20][21]. - A negative Earnings ESP reading, combined with a low Zacks Rank, indicates a challenging outlook for the company to surpass consensus EPS estimates [19][21].

Maskot/DigitalVision via Getty Images In our last assessment, we decided to lower Stevanato Group's (NYSE:STVN) rating due to 'Destocking And Valuation Risk.' As a reminder, having checked Stevanato's peers' lower sales growth estimates in 2024 and anticipating a decline in EBITDA and net profit due to start-up costs and an unfavorable exchange rate effect, the company's valuation was full in our view. No sooner said than done. Following the FY 2023 analysis, Stevanato's share price dropped by almost 30%. T ...

Marco Dal Lago Yes. Our guidance is assuming now a gap compared to prior guidance of approximately €55 million. About the gap, about 65% of the gap is related to vials with more pronounced gap on EZ-fill vials in this period of time. The remaining 25% is associated to the large order we were mentioning and 10% is related to Engineering. So this is the breakdown of the delta we assume today based on, again, the visibility we have, and review guidance for those three reasons. Lisa Miles And Sam, I apologize. ...

(NYSE: STVN) Safe Harbor Statement Forward-Looking Statements For a description of certain additional factors that could cause the Company's future results to differ from those expressed in any such forward-looking statements, refer to the risk factors discussed in our most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. This presentation contains non-GAAP financial measures. Please refer to the tables included in this presentation for a reconciliation of non-GAAP f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F | ☐ | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF | | --- | --- | | | 1934 | | OR | | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the fiscal year ended December 31, 2023 | | OR | | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | OR | | | ☐ | SHELL COMPANY REPORT PURSUANT TO S ...

Revenue Performance - Solid revenue growth of 10% in FY 2023, with an 11% increase on a constant currency basis[12] - Q4 2023 revenue of €87 million, representing a 30% decrease from Q4 2022, while total company revenue increased approximately 24% excluding Covid-19[21] - Reported revenue for Q4 2023 was €320.6 million, up from €292.1 million in Q4 2022, representing a growth of 9.1%[64] - FY 2024 guidance projects revenue between €1.180 billion and €1.210 billion, implying a growth rate of 9% to 12%[29] Profitability Metrics - Adjusted EBITDA of €86.7 million in Q4 2023, a 6% year-over-year increase, with an adjusted EBITDA margin of 27%[20] - Adjusted EBITDA for the year ended December 31, 2023, was €291.5 million, an increase of 13.3% from €257.3 million in 2022[66] - Net profit for Q4 2023 was €45.2 million, a 6% decrease year-over-year, translating to €0.17 diluted EPS[22] - The adjusted operating profit margin for the year ended December 31, 2023, was 19.6%, compared to 20.2% in 2022[66] Capital Expenditures and Investments - Capital expenditures are expected to be 25% to 28% of 2024 revenue, based on the revenue guidance midpoint[30] - The company made additions to Property, Plants, and Equipment totaling €89.6 million in Q4 2023, a decrease of 10.3% from €99.9 million in Q4 2022[77] - Total CAPEX for the year 2023 was €453.3 million, an increase of 49.8% from €302.6 million in 2022[77] - The company recorded €12.0 million in start-up costs for new plants in 2023, primarily related to labor costs for training personnel[68] Future Outlook - The company anticipates a stronger second half of 2024 compared to the first half, with BDS segment growth expected to be low double digits[30] - The company is on track to launch commercial production of new products in late 2024, with significant revenue expected from 2025 onwards[47] - The company expects a net profit range of €155.0 million to €166.6 million for 2024, with diluted EPS projected between €0.58 and €0.63[83] Financial Position - Total backlog at year-end 2023 was approximately €945 million, heavily weighted towards biologics[44] - Capital employed increased to €1,457.1 million as of December 31, 2023, compared to €949.9 million in 2022[72] - The net (debt)/net cash position as of December 31, 2023, was €(324.4) million, a decline from €46.0 million in 2022[74] - Cash Flow from Operating Activities for the year 2023 was €105.2 million, slightly up from €103.3 million in 2022[80] Segment Performance - HVS segment accounted for 37% of total revenue in Q4 2023, with a target of 40% to 45% by 2027[14] - The company expects HVS share of revenue to reach 40% to 45% by 2027, with an adjusted EBITDA margin target of 30% in the same year[50] Other Financial Metrics - Free Cash Flow for Q4 2023 was negative at €(76.0) million, compared to negative €(8.2) million in Q4 2022[80] - Interest paid decreased to €3.1 million in 2023 from €3.5 million in 2022[80] - The purchase of intangible assets increased to €5.1 million in Q4 2023 from €0.3 million in Q4 2022[80] - The company reported a significant increase in additions to intangible assets for the year, totaling €8.7 million compared to €8.1 million in 2022[77]

Stevanato Group S.p.A. (NYSE:STVN) Q4 2023 Earnings Conference Call March 7, 2024 8:30 AM ET Company Participants Lisa Miles - Senior Vice President of Investor Relations Franco Stevanato - Executive Chairman Marco Dal Lago - Chief Financial Officer Franco Moro - Chief Executive Officer Conference Call Participants Patrick Donnelly - Citi Jacob Johnson - Stephens Matt Larew - William Blair Derik de Bruin - Bank of America Larry Solow - CJS Securities David Windley - Jefferies John Sourbeer - UBS Paul Knight ...

The next question is from Jacob Johnson of Stephens. Please go ahead. Yes, you're right in term of what we deliver during Market Day, and yes, we are engaged with important blockbuster coming to the market in the short and to have a bigger volume in the future. There is no changes in this perspective. I wanted to stress the fact that we are talking about biologics in term of kind of molecules that come into the market. And the needs for biologics are perfectly matching our value proposition in a high-value ...